

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/238129169>

# Synthesis and antiplasmodial activity in vitro of new ferrocene?chloroquine analogues Electronic supplementary information (ESI) available: NMR scale synthesis of 7a and <sup>1</sup>H NMR spec...

ARTICLE in DALTON TRANSACTIONS · JULY 2003

Impact Factor: 4.2 · DOI: 10.1039/b303335j

CITATIONS

70

READS

147

8 AUTHORS, INCLUDING:



**Margaret Blackie**

Stellenbosch University

29 PUBLICATIONS 311 CITATIONS

SEE PROFILE



**Reinout Meijboom**

University of Johannesburg

156 PUBLICATIONS 680 CITATIONS

SEE PROFILE



**Peter Smith**

University of Cape Town

247 PUBLICATIONS 4,407 CITATIONS

SEE PROFILE



**Hong Su**

University of Cape Town

43 PUBLICATIONS 332 CITATIONS

SEE PROFILE

# Synthesis and antiparasmodial activity *in vitro* of new ferrocene–chloroquine analogues†

Paul Beagley,<sup>a</sup> Margaret A. L. Blackie,<sup>a</sup> Kelly Chibale,<sup>\*a</sup> Cailean Clarkson,<sup>b</sup> Reinout Meijboom,<sup>a</sup> John R. Moss,<sup>\*a</sup> Peter J. Smith<sup>b</sup> and Hong Su<sup>a</sup>

<sup>a</sup> Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.  
E-mail: jrm@science.uct.ac.za; chibale@science.uct.ac.za

<sup>b</sup> Department of Pharmacology, University of Cape Town Medical School, Observatory 7925, South Africa

Received 24th March 2003, Accepted 6th June 2003

First published as an Advance Article on the web 4th July 2003

The synthesis of the new compounds (7-chloroquinolin-4-yl)-*N'*-(1'-dimethylaminomethylferrocen-1-ylmethyl)-amine (**4a**) and *N*-(7-chloroquinolin-4-yl)-*N'*-(1'-dimethylaminomethylferrocen-1-ylmethyl)-ethane-1,2-diamine (**6a**) is reported. The key step in the synthesis is the cleavage of a ferrocene–Sn bond with *n*-BuLi to give a lithiumferrocenide species (**10**), which is then treated with an electrophile. Thus, 1'-dimethylaminomethyl-1-tri-*n*-butylstannyl-ferrocene (**11**) and subsequently 1'-dimethylaminomethylferrocene-1-carbaldehyde (**7a**) were synthesised from 1,1'-bis(tri-*n*-butylstannyl)ferrocene, employing [CH<sub>2</sub>=NMe<sub>2</sub>]I and DMF to introduce the amine and then the aldehyde functionalities. In addition, the compound 1'-dimethylaminomethyl-1-lithiumferrocenide was isolated and the <sup>1</sup>H and <sup>13</sup>C NMR data are reported. X-Ray crystal and molecular structures are reported for compound **4a** and the related compound *N*-(7-chloroquinolin-4-yl)-*N'*-(2-dimethylaminomethylferrocen-1-ylmethyl)-ethane-1,2-diamine (**5a**). The antiparasmodial activity *in vitro* against chloroquine sensitive and resistant strains of *Plasmodium falciparum* is reported and compared to a series of ferrocene, ruthenocene and phenylene analogues.

## Introduction

Chloroquine (**1**, see Fig. 1) has been an effective antimalarial agent since the late 1940s. Unfortunately, in most affected areas, the causative agent *Plasmodium falciparum* has developed resistance to chloroquine and other quinoline antimalarials.<sup>1</sup> Since malaria affects between 300 and 500 million people each year and is responsible for 1.5 to 2.7 million fatalities, the emergence of quinoline drug resistance is a major problem.<sup>2</sup> To overcome this problem numerous aminoquinolines<sup>3</sup> and aminoquinoline metal complexes<sup>4</sup> have been screened against *P. falciparum*; of these ferroquine (**2a**)<sup>5</sup> shows the greatest promise and clinical trials are currently in progress.

To establish the role of the iron/ferrocene in ferroquine we have performed preliminary structure–activity relationship studies.<sup>6</sup> As part of this work we have prepared a series of 7-chloro-4-aminoquinolines with amino alkyl side chains containing the ferrocene,<sup>7</sup> ruthenocene<sup>8</sup> and phenylene<sup>6</sup> moieties. The synthesis of the ruthenocene analogues resulted in the

unexpected synthesis of 4-aminoquinolines with 1,1'-disubstituted ruthenocenes in the side chain *e.g.* **4b** (isoruthenoquine) and **6b**.<sup>8</sup> To extend structure–activity relationships, we have now synthesised the corresponding ferrocene complexes **4a** (isoferroquine) and **6a**. We have also had to develop a new synthetic route since ferrocene and ruthenocene differ significantly in reactivity.

## Results and discussion

The key intermediate for the synthesis of isoruthenoquine (**4b**), and **6b** is the complex **7b** (see Scheme 1).<sup>8</sup> Unfortunately, the corresponding iron complex **7a** is not readily accessible. When the methodology employed to synthesise **7b** was applied to the ferrocene system the 1,2-isomer was formed exclusively and not the desired 1,1'-isomer. Although **7a** is described in the literature, poor selectivity and low yields were reported.<sup>9</sup>

We have now achieved a higher yielding synthesis of **7a** by employing 1,1'-bis(tri-*n*-butylstannyl)ferrocene (**9**). The key to this route is the selective and sequential removal of the tri-*n*-butylstannyl groups with *n*-BuLi in THF at –78 °C.<sup>10</sup> Firstly, 1'-tri-*n*-butylstannyl-1-lithiumferrocenide (**10**) is generated and reacted with Eschenmoser's salt, ([CH<sub>2</sub>=NMe<sub>2</sub>]I), to introduce






Fig. 1 Chloroquine (**1**) and analogues of current interest (**2a–6b**).

† Electronic supplementary information (ESI) available: NMR scale synthesis of **7a** and <sup>1</sup>H NMR spectrum of **12**. See <http://www.rsc.org/suppdata/dt/b3/b303335j/>



Scheme 1



Scheme 2

the dimethylaminomethyl moiety. The resulting complex 1'-dimethylaminomethyl-1-tri-*n*-butylstannylferrocene (**11**) is then reacted with *n*-BuLi in THF at  $-78^{\circ}\text{C}$  to generate 1'-dimethylaminomethyl-1-lithiumferrocenide (**12**) which is reacted with DMF to yield the desired product **7a** in high yield (see Scheme 2).<sup>‡</sup>

The aldehyde **7a** was then converted to the oxime and reduced to the primary amine **8a** with  $\text{LiAlH}_4$  (Scheme 1). Condensation of **8a** with 4,7-dichloroquinoline yielded **4a** as a yellow crystalline solid in 74% yield. Complex **6a** was prepared as an orange oil in 66% yield by reductive amination of **7a** with *N*-(7-chloroquinolin-4-yl)-ethane-1,2-diamine (see Scheme 1).

Since we were able to prepare **7a** in high yield from **11** without forming any of the 1,2-isomer, and we have previously isolated lithiated carbosilane dendrimers<sup>11</sup> using this methodology, we thought it would be interesting to isolate **12**. Compound **12** was generated in THF at  $-78^{\circ}\text{C}$  as before, the solvent was removed *in vacuo* and the  $\text{Bu}_4\text{Sn}$  was washed out with pentane to yield **12** as an orange-red solid. This solid was stable at room temperature (24 h) but was air- and moisture-sensitive; reaction of this solid with DMF yielded **7a** quantitatively. The  $^1\text{H}$  NMR spectrum of **12**, thus isolated, did not contain THF which is known to coordinate strongly to RLi compounds.<sup>12</sup> NMR spectra of pure **12** were run at  $60^{\circ}\text{C}$  to ensure dissolution in  $\text{C}_6\text{D}_6$ , possibly causing the  $\text{Me}_2\text{N}$ -group to dissociate from the lithium. When the synthesis of **7a** from **11** was performed on an NMR scale (see ESI<sup>†</sup>), coordination of THF was observed. The NMR scale synthesis of **7a** also revealed that all reactions were selective, fast and quantitative.

#### Assessment of antimalarial activity *in vitro*

The data for the *in vitro* activity against both chloroquine sensitive and resistant strains of *P. falciparum* is shown in Table 1. Data for chloroquine, and a number of ferrocene, ruthenocene

**Table 1** Results of *in vitro* antimalarial tests conducted on the chloroquine sensitive (D10) and resistant (K1) strains of *P. falciparum*

Compound	D10		K1	
	$\text{IC}_{50}/\text{ng mL}^{-1}$	$\text{IC}_{50}/\text{nM}$	$\text{IC}_{50}/\text{ngm L}^{-1}$	$\text{IC}_{50}/\text{nM}$
1·2H <sub>3</sub> PO <sub>4</sub>	12	23	182	352
<b>2a</b>	8	18	18	14
<b>2b</b>	9	19	6	13
<b>3</b>	4	13	2	7
<b>4a</b>	8	19	21	49
<b>4b</b>	12	25	14	29
<b>5a</b>	16	33	18	37
<b>5b</b>	10	20	10	20
<b>6a</b>	7	16	31	65
<b>6b</b>	18	34	66	127

and phenylene compounds have also been included for comparison. It is difficult to delineate meaningful structure-activity relationships from the small statistical group presented in Table 1 however it is evident that: (i) despite the diverse range of side-chains employed, all the compounds show moderate to strong antiplasmodial activity against the chloroquine sensitive (D10) strain of the parasite. (ii) The 1,1'-disubstituted compounds **4a**, **4b**, **6a** and **6b** exhibited lower antiplasmodial activity against the chloroquine resistant (K1) than against the chloroquine sensitive (D10) strain of the parasite. Nevertheless, it is noteworthy that these compounds were still more active than chloroquine in the K1 strain. (iii) Compared to the 1,1'-disubstituted compounds (**4a** and **4b**), the 1,2-disubstituted metallocenes (**2a** and **2b**) exhibited high activity in the chloroquine resistant (K1) strain of the parasite. (iv) These results confirm the previously reported equipotency of ruthenocene and ferrocene analogues.<sup>8</sup>

In view of the data obtained for the phenylequine **3** this work suggests that the primary role of the metallocene is to act as a hydrophobic spacer. The increased lipophilicity may aid passage through membranes or may lead to a greater affinity for  $\beta$ -haematin. Whether a secondary toxicity is associated with the ferrocene is not clear. The stereochemistry around the metallocene appears to influence the capacity of these compounds to

<sup>‡</sup> Despite the strong *ortho*-directing effect of the  $\text{Me}_2\text{NCH}_2$ -moiety the 1,1'-disubstituted ferrocene **11** was the only product observed when the crude mixture was analysed using  $^1\text{H}$  NMR spectroscopy.

**Table 2** Hydrogen bonding interactions for complexes **4a**·H<sub>2</sub>O, **4b**·H<sub>2</sub>O and **5a**


Compound	Donor(D)–H ... Acceptor(A)	Bond distances/Å			Bond angles/°
		D–H	H ... A	D ... A	D–H ... A
<b>4a</b>	N2–H2 ... O1W	0.97(2)	2.01(1)	2.957(3)	164(3)
	O1W–H1W ... N3 <sup>a</sup>	0.99(2)	1.89(1)	2.835(3)	159(4)
	O1W–H2W ... N1 <sup>b</sup>	0.99(2)	1.98(1)	2.967(3)	174(3)
<b>4b</b>	N2–H2 ... O1W <sup>a</sup>	0.97(1)	2.02(2)	2.962(2)	164(2)
	O1W–H1W ... N3	0.99(1)	1.87(2)	2.853(3)	171(3)
	O1W–H2W ... N1 <sup>c</sup>	0.99(1)	2.01(2)	2.983(2)	167(2)
<b>5a</b>	N2–H2 ... N1 <sup>d</sup>	0.97(1)	2.11(1)	3.050(2)	163(2)
	N1–H1 ... N4	0.97(1)	2.29(1)	3.171(2)	151(1)

Symmetry code: a  $x + 1/2, -y + 3/2, z + 1/2$ . b  $x, y + 1, z$ . c  $x - 1/2, -y + 5/2, z - 1/2$ . d  $-x + 1, -y + 1, -z + 1$ .

circumvent the parasite's resistance mechanism. The results in the D10 strain suggest the stereochemistry has a less significant effect on the antiplasmodial activity.

### X-Ray crystallography

**Molecular structure of (7-chloroquinolin-4-yl)-N'-(1'-dimethylferrocen-1-ylmethyl)-amine hydrate **4a**·H<sub>2</sub>O.** The molecular structure of **4a**, excluding the water molecule, is shown in Fig. 2. It is isostructural to that of the monohydrated ruthenocene analogue, **4b**·H<sub>2</sub>O, which has been previously reported.<sup>8</sup> The conformation of the ferrocene is almost eclipsed with torsional angles varying from 9.5(4)° to 11.8(3)°. The Fe–Cp centroid distances are 1.653(2) and 1.654(2) Å. The asymmetric unit of this compound contains a water molecule which behaves as a hydrogen bond donor for the tertiary amine and the quinoline N atom, and also accepts a hydrogen bond from the secondary amine. This hydrogen bonding pattern closely resembles that observed for **4b**·H<sub>2</sub>O. The hydrogen bonding geometries for both **4a**·H<sub>2</sub>O and **4b**·H<sub>2</sub>O are given in Table 2 for comparison.



to literature methods. Tetrahydrofuran was distilled from Na/benzophenone; pentane was distilled from Na/benzophenone/tetraglyme; methanol was distilled from magnesium activated by iodine, 1-methylpyrrolidinone was purified by an azeotropic distillation from toluene and DMF was distilled from CaSO<sub>4</sub> (76 °C/39 mmHg). The concentration of alkyllithium reagents was determined by the Gilman double titration method prior to use.<sup>15</sup> TMEDA was distilled from sodium. C<sub>6</sub>D<sub>6</sub> was distilled from Na/K. All other chemicals were used as supplied by Aldrich. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded at room temperature on Varian EM 400 or 300 MHz spectrometers. <sup>1</sup>H NMR spectra were referenced internally using the residual protons in the deuterated solvent (CDCl<sub>3</sub>: δ 7.27, C<sub>6</sub>D<sub>6</sub>: δ 7.16) and are reported relative to tetramethylsilane (δ 0.00). <sup>13</sup>C NMR spectra were referenced internally to the solvent resonance (CDCl<sub>3</sub>: δ 77.0, C<sub>6</sub>D<sub>6</sub>: δ 128.0) and are reported relative to tetramethylsilane (δ 0.0). Infrared spectra were recorded on a Perkin-Elmer Paragon 1000 FT-IR spectrometer. Melting points were performed on a Kofler hot-stage microscope (Reichert-Thermovar). Mass spectra were determined by Dr P. Boshof at the Cape Technikon. The *m/z* values quoted refer to the most abundant isotopes, in all cases the isotopic distribution corresponded to theoretical distribution. Elemental analyses were performed using a Carlo Erba EA1108 elemental analyser in the microanalytical laboratory of the University of Cape Town.

## Syntheses

**1'-(*N,N*-Dimethylaminomethyl)-1-tri-*n*-butylstannyl-ferrocene 11.** *n*-BuLi (12.8 cm<sup>3</sup>, 18 mmol of a 1.4 M solution in hexanes) was added to a solution of 1,1'-bis(tri-*n*-butylstannyl)ferrocene (13.1 g, 17 mmol) in THF (160 cm<sup>3</sup>) at –78 °C and stirred for 0.5 h. Eschenmoser's salt (3.35 g, 18 mmol) was added *via* a Merlic addition funnel. The reaction mixture was allowed to warm to 25 °C and stirred for a further 16 h. The solvent was removed *in vacuo* and the red oil was dissolved in diethyl ether (150 cm<sup>3</sup>) and washed with water (50 cm<sup>3</sup>), the aqueous phase was removed and washed with diethyl ether (2 × 50 cm<sup>3</sup>), the organic fractions were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent removed *in vacuo*. Purification by column chromatography on alumina (Brockman V) eluting with hexane to remove unreacted 1,1'-bis(tri-*n*-butylstannyl)ferrocene first, followed by hexane–diethyl ether–triethylamine 70 : 29 : 1 to elute the title product as an orange oil (6.45 g, 67%) (Found: C, 56.77; H, 8.27; N, 2.65. FeSn<sub>3</sub>C<sub>25</sub>H<sub>43</sub>N calculated C, 56.42; H, 8.14; N, 2.63%;  $\tilde{\nu}_{\max}$ /cm<sup>–1</sup> 3093w (br), 2950s, 2923s, 2860m, 2808m, 2705m (br), 1461m, 1382w, 1345w, 1265w, 1176w, 1138w, 1037w, 1026w, 824w (NaCl neat);  $\delta_{\text{H}}$  (400 MHz; solvent C<sub>6</sub>D<sub>6</sub>) 4.15 (2 H, m), 4.12 (2 H, m), 4.01 (2 H, m), 3.95 (2 H, m), 3.25 (2 H, s), 2.09 (6 H, s, NMe<sub>2</sub>), 1.58–1.68 (6 H, m), 1.30–1.45 (6 H, m), 1.01–1.10 (6 H, m), 0.91 (9 H, t, <sup>3</sup>J(HH) 8 Hz);  $\delta_{\text{C}}$  (100 MHz; solvent CDCl<sub>3</sub>) 84.1 (Cp<sup>IV</sup>), 75.1 (<sup>2</sup>J(CC<sup>117/119</sup>Sn) 42 Hz Cp–H), 71.5 (<sup>3</sup>J(CCC<sup>117/119</sup>Sn) 35 Hz), 70.3 (Cp–H), 68.7 (Cp<sup>IV</sup>), 68.1 (Cp–H), 59.6 (CH<sub>2</sub>–N), 44.8 (–NMe<sub>2</sub>), 29.5 (<sup>3</sup>J(CCC<sup>117/119</sup>Sn) 19 Hz), 27.6 (<sup>2</sup>J(CC<sup>117/119</sup> 56 Hz), 13.7 (Me), 10.5 (<sup>1</sup>J(C<sup>117/119</sup>Sn) 346/329 Hz); *m/z* (FAB) found 533.1767 (100%), Fe<sup>120</sup>Sn<sub>3</sub>C<sub>25</sub>H<sub>43</sub>N requires 533.1767, 489 (M – NMe<sub>2</sub>, 85), 476 (M – CH<sub>2</sub>NMe<sub>2</sub>, 86), 431 (M – NMe<sub>2</sub> – Bu, 61), 362 (M – 3Bu) 319 (M – NMe<sub>2</sub> – 3Bu), 242 (M – SnBu<sub>3</sub>, 49), 235 (54), 199 (87), 179 (79).

**1'-Dimethylaminomethylferrocene-1-carbaldehyde 7a.** *n*-BuLi (4.4 cm<sup>3</sup>, 6.2 mmol, of a 1.4 M solution in hexanes) was added to a mixture of 1'-dimethylaminomethyl-1-tri-*n*-butylstannylferrocene (3.0 g, 1.5 mmol) in THF (15 cm<sup>3</sup>) at –78 °C and stirred for 0.5 h. To this mixture *N,N*-dimethylformamide (5 cm<sup>3</sup>) was added and stirred for a further 3 h allowing the mixture to warm to 25 °C. The solvent was removed *in vacuo* and the red oil was dissolved in diethyl ether (100 cm<sup>3</sup>) and

washed with water (30 cm<sup>3</sup>), the aqueous phase was removed and washed with diethyl ether (2 × 50 cm<sup>3</sup>), the organic fractions were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent removed *in vacuo*. Column chromatography on silica eluting with diethyl ether–hexane–triethylamine 70 : 20 : 10 yielded the title product as an orange oil (1.4 g, 92%),  $\tilde{\nu}_{\max}$ /cm<sup>–1</sup> 3092w, 2933w (br), 2862w, 2827w, 2770w, 1679s (CO), 1455m (NMe<sub>2</sub>), 1245m, 1040w, 1028w, 846m, 743w (neat NaCl);  $\delta_{\text{H}}$  (solvent CDCl<sub>3</sub>; 300 MHz) 9.88 (1 H, s), 4.62 (2 H, m), 4.49 (2 H, m), 4.21 (2 H, m), 4.16 (2 H, m), 3.12 (2 H, s), 2.09 (6 H, s);  $\delta_{\text{C}}$  (solvent CDCl<sub>3</sub>, 75 MHz) 193.1 (CHO), 85.5, 79.6 (Cp<sup>IV</sup>), 73.6, 71.4, 69.9, 69.5 (Cp–H), 58.2 (–CH<sub>2</sub>), 44.6 (–NMe<sub>2</sub>); *m/z* (FAB) found 271.0660, C<sub>14</sub>H<sub>17</sub>NOFe requires 271.0660, 256 (M – Me, 22%), 242 (M – 30), 227 (M – NMe<sub>2</sub>, 100), 199 (M – NMe<sub>2</sub> – CHO, 49), 154 (19), 136 (23).

**1'-Dimethylaminomethylferrocene-1-carbaldehyde oxime.** A solution of sodium hydroxide (0.72 g, 18 mmol) in water (4.5 cm<sup>3</sup>) was added to a stirred mixture of freshly prepared 1'-dimethylaminomethylferrocene-1-carbaldehyde **7a** (1.20 g, 4.4 mmol) and hydroxylamine hydrochloride (625 mg, 9 mmol) in ethanol (35 cm<sup>3</sup>) at room temperature. The resulting mixture was heated under reflux for 4 h and allowed to cool. Water (3 cm<sup>3</sup>) was added and the mixture was neutralised by the addition of CO<sub>2</sub>(s). The product was extracted with dichloromethane (3 × 20 cm<sup>3</sup>), dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent removed *in vacuo* to yield an orange semi-solid (1.23 g, 98%),  $\tilde{\nu}_{\max}$ /cm<sup>–1</sup> 3774w (br), 3185w (br), 3088w, 2976w, 2964m, 2939m, 2864m, 2820m, 2685w, 1598s, 1448s, 1374m, 1344m, 1344m, 1292m, 1158s, 1039s, 956w, 830w, 733m, 695m (NaCl neat);  $\delta_{\text{H}}$  (solvent CDCl<sub>3</sub>; 300 MHz) 7.89 (1 H, s), 4.49 (2 H, m), 4.26 (4 H, m), 4.16 (2 H, m), 3.36 (2 H, s), 2.20 (6 H, s);  $\delta_{\text{C}}$  (solvent CDCl<sub>3</sub>, 75 MHz) 148.0 (C=NOH), 83.0, 77.6 (Cp<sup>IV</sup>), 71.4, 70.2, 69.4, 67.8 (Cp–H), 58.3 (–CH<sub>2</sub>), 44.0 (–NMe<sub>2</sub>); *m/z* (FAB) found 286.0777, C<sub>14</sub>H<sub>18</sub>ON<sub>2</sub>Fe requires 286.0786, 269 (M – OH, 21%), 242 (M – NMe<sub>2</sub>, 100), 225 (M – NMe<sub>2</sub> – OH, 31), 194 (11), 176 (6).

**1'-Aminomethyl-1-dimethylaminomethylferrocene 8.** A mixture of LiAlH<sub>4</sub> (0.6 g, 16 mmol) and 1-dimethylaminomethylferrocene-1'-carboxaldehyde oxime (1.2 g, 4 mmol) in THF (100 cm<sup>3</sup>) was heated under reflux for 6 h. The cooled solution was diluted with diethyl ether (25 cm<sup>3</sup>), quenched with water, washed with brine (2 × 10 cm<sup>3</sup>), dried over anhydrous K<sub>2</sub>CO<sub>3</sub>, filtered and the solvent removed *in vacuo* to yield a brown oil (1.05 g, 97%),  $\tilde{\nu}_{\max}$ /cm<sup>–1</sup> 3371m (br), 3289m (br), 2931s, 2857s, 2820s, 2767s, 1637w, 1597w, 1456w, 1381w, 1351w, 1262w, 1240w, 1173w, 1038s, 912m, 830s, 733s (NaCl neat);  $\delta_{\text{H}}$  (solvent CDCl<sub>3</sub>; 400 MHz) 4.09 (2 H, m), 4.05 (4 H, m), 4.02 (2 H, m) 3.51 (2 H, s), 3.23 (2 H, s), 2.13 (6 H, s);  $\delta_{\text{C}}$  (solvent CDCl<sub>3</sub>, 100 MHz) 91.0, 83.5 (Cp<sup>IV</sup>), 70.3, 68.3, 68.2, 67.6 (Cp–H), 59.0 (CH<sub>2</sub>NMe<sub>2</sub>), 44.7 (–NMe<sub>2</sub>), 41.1 (–CH<sub>2</sub>NH<sub>2</sub>); *m/z* (FAB) found 272.0970, C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>Fe requires 272.0976, 256 (M – NH<sub>2</sub>, 43%), 242 (M – 2Me, 17), 228 (M – NMe<sub>2</sub>, 100), 213 (M – NMe<sub>2</sub>, NH<sub>2</sub>), 199 (M – CH<sub>2</sub>NMe<sub>2</sub>, NH<sub>2</sub>, 17), 178 (11) 135 (15).

**Isoferroquine 4a.** A mixture of **8a** (0.60 g, 2.2 mmol), 4,7-dichloroquinoline (2.38 g, 12 mmol), Na<sub>2</sub>CO<sub>3</sub> (50 mg), triethylamine (3 cm<sup>3</sup>) and 1-methylpyrrolidinone (8 cm<sup>3</sup>) was heated to 130 °C and stirred for 6 h. The product was extracted with ethyl acetate (75 cm<sup>3</sup>) and washed with brine (10 × 40 cm<sup>3</sup>), the organic layer was then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was removed *in vacuo*. The product was purified by silica gel chromatography eluting with ethyl acetate–hexane–triethylamine 80 : 15 : 5. Recrystallisation from ethyl acetate and hexane gave yellow microcrystals (703 mg, 74%), mp 118 °C (Found: C, 63.94; H, 5.50; N, 9.46. FeC<sub>23</sub>H<sub>24</sub>N<sub>3</sub>Cl requires C, 63.69; H, 5.58; N, 9.69%;  $\tilde{\nu}_{\max}$ /cm<sup>–1</sup> 3685m (br) (intermolecular H-bond), 3609 (br) (intermolecular H-bond), 3437w (br),

**Table 3** Crystal data and structural refinement for **4a** and **5a**

	<b>4a</b>	<b>5a</b>
Empirical formula	FeC <sub>23</sub> H <sub>24</sub> ClN <sub>3</sub> ·H <sub>2</sub> O	FeC <sub>25</sub> H <sub>29</sub> N <sub>4</sub> Cl
Formula weight	451.77	476.82
Temperature/K	193(2)	173(2)
Wavelength/Å	0.71073	0.71073
Space group	C2/c	P2 <sub>1</sub> /c
Crystal system	Monoclinic	Monoclinic
<i>a</i> /Å	26.3704(2)	10.7012(3)
<i>b</i> /Å	9.2289(3)	16.2573(4)
<i>c</i> /Å	21.7319(4)	13.7853(3)
$\beta$ /°	127.221(1)	92.727(1)
Volume/Å <sup>3</sup>	4211.6(2)	2395.6(1)
<i>Z</i>	8	4
Absorption coefficient/mm <sup>-1</sup>	0.862	0.760
Reflections collected	32757	10265
Independent reflections	4830 [ <i>R</i> (int) = 0.0670]	5459 [ <i>R</i> (int) = 0.0240]
Final <i>R</i> indices [ <i>I</i> > 2 $\sigma$ ( <i>I</i> )]	<i>R</i> 1 = 0.0440, <i>wR</i> 2 = 0.1069	<i>R</i> 1 = 0.0338, <i>wR</i> 2 = 0.0750
<i>R</i> indices (all data)	<i>R</i> 1 = 0.0763, <i>wR</i> 2 = 0.1372	<i>R</i> 1 = 0.0546, <i>wR</i> 2 = 0.0825

3063s, 3049s, 2856w, 2821w, 2775w, 1611 (C=N quinoline), 1583m, 1521w, 1470w (br), 1421w, 1374w, 1334m, 1286s, 1274s, 1264s, 1132w, 1097s, 1024s (CH<sub>2</sub>Cl<sub>2</sub>);  $\delta_{\text{H}}$  (solvent CDCl<sub>3</sub>; 400 MHz) 8.57 (1 H, d <sup>3</sup>*J*(HH) 6 Hz), 7.98 (1 H, d <sup>3</sup>*J*(HH) 2 Hz), 7.68 (1 H, <sup>3</sup>*J*(HH) 9 Hz), 7.37 (1 H, dd, <sup>3</sup>*J*(HH) 9 Hz, <sup>4</sup>*J*(HH) 2 Hz), 6.49 (1 H, d, <sup>3</sup>*J*(HH) 5 Hz), 5.32 (1 H, br NH), 4.24 (2 H, m), 4.18 (6 H, m), 4.14 (2 H, d (HH) 5 Hz), 3.30 (2 H, s), 2.19 (6 H, s);  $\delta_{\text{C}}$  (solvent CDCl<sub>3</sub>; 75 MHz) 151.8 (CH), 149.2, 148.9, 134.7 (C<sup>IV</sup>), 128.5, 125.1, 121.0 (CH) 117.0 (C<sup>IV</sup>), 99.0 (CH), 84.4, 83.9 (Cp<sup>IV</sup>), 70.4, 68.9, 68.7, 68.5 (Cp-H), 58.7 (CH<sub>2</sub>), 44.7 (NMe<sub>2</sub>), 41.2 (CH<sub>2</sub>); *m/z* (FAB) found 434.1099, C<sub>23</sub>H<sub>25</sub>N<sub>3</sub>FeCl requires 434.1086, 386 (M - NMe<sub>2</sub>, 100), 311 (M - CpCH<sub>2</sub>-NMe<sub>2</sub>, 43), 256 (M - CpFeCH<sub>2</sub>NMe<sub>2</sub>, 25).

***N*-(7-Chloroquinolin-4-yl)-*N'*-(1'-dimethylaminomethyl-ferrocene-1-ylmethyl)-ethane-1,2-diamine **6a**.** Compound **7a** (271 mg, 1 mmol) and *N*<sup>1</sup>-(7-chloroquinolin-4-yl)-ethane-1,2-diamine (222 mg, 1 mmol) were dissolved in methanol (10 cm<sup>3</sup>) and stirred for 16 h. Sodium borohydride (0.100 mg, 2.6 mmol) was added and the mixture was stirred for a further 1 h. The solvent was removed *in vacuo*, the residue was dissolved in ethyl acetate (40 cm<sup>3</sup>) and washed with brine (3 × 10 cm<sup>3</sup>), the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent removed *in vacuo*. The product was purified by silica gel chromatography slowly increasing the polarity from EtOAc-MeOH-triethylamine; 94 : 4 : 2 to 75 : 15 : 10 to yield an orange oil (315 mg, 66%) (Found: C, 63.08; H, 6.72; N, 11.42). FeC<sub>23</sub>H<sub>24</sub>N<sub>3</sub>Cl requires C, 62.84; H, 6.33; N, 11.73%;  $\tilde{\nu}_{\text{max}}$ /cm<sup>-1</sup> 3693 (intermolecular H-bond), 3597 (br) (intermolecular H-bond), 3055s, 3045s, 2932m (br), 2856w (br), 2770w, 1609 (C=N quinoline), 1583s, 1528m (br), 1472w, 1369w, 1333w, 1272s, 1261m, 1254s, 1136w, 1078w, 1040w, 905m, 890, 868s, 821s, 811, (CH<sub>2</sub>Cl<sub>2</sub>);  $\delta_{\text{H}}$  (400 MHz; solvent CDCl<sub>3</sub>) 8.37 (1 H, d, <sup>3</sup>*J*(HH) 5 Hz), 7.83 (1 H, d, <sup>4</sup>*J*(HH) 2 Hz), 7.70 (1 H, d, <sup>3</sup>*J*(HH) 9 Hz), 7.20 (1 H, dd, <sup>3</sup>*J*(HH) 9 Hz, <sup>4</sup>*J*(HH) 2 Hz), 6.23 (1 H, d, <sup>3</sup>*J*(HH) 5 Hz), 6.15 (1 H, br s, NH), 4.04 (4 H, m), 3.99–4.01 (4 H, m), 3.49 (2 H, s), 3.25 (2 H, m), 3.20 (2 H, s), 2.92 (2 H, m), 2.08 (6 H, s);  $\delta_{\text{C}}$  (100 MHz; solvent CDCl<sub>3</sub>) 151.6 (CH), 150.0, 148.7, 134.7 (C<sup>IV</sup>), 128.0 (CH), 124.9 (C-H), 121.8 (CH), 117.3 (C<sup>IV</sup>), 98.9 (CH), 85.9, 83.1 (Cp<sup>IV</sup>), 70.5, 70.0, 68.6, 68.6 (Cp-H), 58.7, 48.1, 46.7 (CH<sub>2</sub>), 44.4 (NMe<sub>2</sub>), 42.0 (CH<sub>2</sub>); *m/z* (FAB) found 477.15084 (M + H - FeC<sub>25</sub>H<sub>31</sub>N<sub>4</sub>Cl requires 477.15106), 432 (M - NMe<sub>2</sub>, 41%), 354 (M - Cp - CH<sub>2</sub>NMe<sub>2</sub>, 38), 276 (16), 256 (52), 240 (26), 213 (100), 191 (14), 178 (13), 162 (12), 135 (34).

**Isolation of **12**.** A solution of *n*-BuLi (0.65 cm<sup>3</sup>, of a 1.54 M solution in hexanes, 1.0 mmol) was added to a solution of 1'-dimethylaminomethyl-1-tri-*n*-butylstannylferrocene (0.53 g, 1.0 mmol) in THF (5.0 cm<sup>3</sup>) at -78 °C in the primary chamber

of an H-type Schlenk-tube.<sup>16</sup> The mixture was stirred for 30 min at -78 °C, during which time a precipitate formed. Several drops of *n*-BuLi in hexane were added to the secondary chamber of the H-type Schlenk-tube. The volatiles were removed *in vacuo* to leave an orange-red solid and an oil. Pentane (2.0 cm<sup>3</sup>) was added to the *n*-BuLi in the secondary chamber and distilled onto the reaction mixture (through this extra drying procedure pure solvents were guaranteed). Residual THF was removed by distilling pentane (3 × 2 cm<sup>3</sup>) onto the mixture and then removing the pentane *in vacuo*. The mixture in the primary chamber was then washed with pentane (3 × 10 cm<sup>3</sup>) by distilling the solvent onto the lithiated ferrocene and filtering to the secondary chamber. The volatiles were removed *in vacuo* to leave **12** as a red solid in the primary chamber and a red oil (SnBu<sub>4</sub> + BuLi + unreacted traces of starting material) in the secondary chamber.  $\delta_{\text{H}}$  (300 MHz; solvent C<sub>6</sub>D<sub>6</sub>, 60 °C) 4.60 (2 H, m), 4.11–4.20 (4 H, m), 3.87 (2 H, m), 2.76 (2 H, s), 2.06 (6 H, s);  $\delta_{\text{C}}$  (75 MHz; solvent C<sub>6</sub>D<sub>6</sub>) 83.6, 80.6 (Cp<sup>IV</sup>), 72.1 (2Cp-H), 67.3 (4Cp-H), 67.1 (2Cp-H), 58.6 (CH<sub>2</sub>N), 47.0 (NMe<sub>2</sub>).

#### Cultivation of malaria parasites

Two strains of *P. falciparum* were used in this study, a chloroquine sensitive strain D10 and a chloroquine resistant strain K1. The *P. falciparum* strains were cultured using a modified version of the Trager and Jensen method.<sup>17</sup> The parasites are maintained in RPMI 1640 (BioWhittaker) culture medium, to which is added 40 mg cm<sup>-3</sup> gentamycin (Lennon), 1% sodium bicarbonate, 0.5% Albumax (lipid rich bovine serum albumin) and O<sup>+</sup> human red blood cells (Transfusion Services and Haematology Department, UCT/Groote Schuur Hospital). The cultures are contained in flat bottom flasks and incubated at 37 °C with a controlled gas environment of 4% CO<sub>2</sub>, 3% O<sub>2</sub> and 93% N<sub>2</sub>. The medium is changed at frequent intervals and parasite cultures are fed to maintain an optimum 3–5% parasitaemia and a 2–4% haematocrit. The parasitaemia is determined using Giemsa stained blood films of the cultures. Synchronisation of cultures is achieved by a brief exposure to a 5% D-sorbitol solution.

#### X-Ray crystallography

Crystals of complex **4a**·H<sub>2</sub>O were obtained by slow diffusion of hexane into a wet ethylacetate solution of **4a**. Crystals of **5a** were obtained by slow diffusion of diethyl ether into an acetonitrile solution of **5a**. X-Ray diffraction data for compounds **4a** and **5a** were collected on a Nonius Kappa CCD with 1.5 kW graphite monochromated Mo radiation. The strategy for the data collection was evaluated using COLLECT.<sup>18</sup> The data were integrated, scaled and reduced with DENZO-SMN.<sup>19</sup> The structures were solved and refined with SHELX97.<sup>20</sup> The H

atoms belonging to amino groups were located in the Fourier maps and refined with the N–H distances constrained. Although we could locate all other H atoms, they were placed in idealised positions and refined as riding atoms. Molecular graphics were obtained with POV-Ray using an X-Seed interface.<sup>21</sup> A selection of crystal and refinement data is given in Table 3.

CCDC reference numbers 206811 and 206812.

See <http://www.rsc.org/suppdata/dt/b3/b303335j/> for crystallographic data in CIF or other electronic format.

## Acknowledgements

We would like to thank Johnson Matthey for the loan of ruthenium trichloride, the Claude Harris Leon Foundation, the University of Cape Town, THRIP and the National Research Foundation (South Africa) for financial support. We would like to thank John Bacsá for his assistance with the X-ray crystallography. We would also like to thank Professor Jacques Brocard for helpful discussions.

## References

- 1 P. A. Winstanley, *Parasitol. Today*, 2000, **16**, 146.
- 2 Weekly Epidemiological Record, W.H.O., 1997, **vol. 72 (No I, II, III)**, p. 1.
- 3 T. J. Egan, *Expert Opin. Ther. Pat.*, 2001, **11**, 185 and references therein.
- 4 (a) R. A. Sánchez-Delgado, M. Navarro, H. Pérez and J. A. Urbina, *J. Med. Chem.*, 1996, **39**, 1095; (b) M. Navarro, H. Pérez and R. A. Sánchez-Delgado, *J. Med. Chem.*, 1997, **40**, 1937; (c) N. Wasi and H. B. Singh, *Synth. React. Inorg. Met.-Org. Chem.*, 1988, **18**, 473; (d) N. Wasi and H. B. Singh, *Synth. React. Inorg. Met.-Org. Chem.*, 1987, **17**, 129; (e) N. Wasi, H. B. Singh, A. Gajanana and A. N. Raichowdhary, *Inorg. Chim. Acta*, 1987, **135**, 133.
- 5 C. Biot, G. Glorian, L. A. Maciewski, J. S. Brocard, O. Domarle, G. Blampain, P. Millet, A. J. Georges, H. Abessolo, D. Dive and J. Lebib, *J. Med. Chem.*, 1997, **40**, 3715.
- 6 M. A. L. Blackie, P. Beagley, J. R. Moss, H. Kendrick, S. L. Croft and K. Chibale, submitted for publication.
- 7 K. Chibale, J. R. Moss, M. Blackie, D. van Schalkwyk and P. J. Smith, *Tetrahedron Lett.*, 2000, **41**, 6231.
- 8 P. Beagley, M. A. L. Blackie, K. Chibale, C. Clarkson, J. R. Moss and P. J. Smith, *J. Chem. Soc., Dalton Trans.*, 2002, 4426.
- 9 (a) S. Picart-Goetgheluck, O. Delacroix, L. Maciejewski and J. Brocard, *Synthesis*, 2000, **10**, 1421; (b) K. Schlögl and M. Walser, *Tetrahedron Lett.*, 1968, **9**, 5885.
- 10 M. E. Wright, *Organometallics*, 1990, **9**, 853.
- 11 R. Meijboom, A. T. Hutton and J. R. Moss, *Organometallics*, 2003, **22**, 1811.
- 12 M. Schlosser, in *Organometallics in Synthesis, a manual*, ed. M. Schlosser, Wiley, Chichester, 1994, ch 1.2, pp. 9–11.
- 13 D. De, L. D. Byer and D. J. Krogstad, *Heterocyclic Chem.*, 1997, **34**, 315.
- 14 I. R. Butler, in *Inorganic Experiments*, ed. J. D. Woollins, VCH, Weinheim, 1994, ch. 3, pp. 61–66.
- 15 G. S. Silverman, in *Handbook of Grignard Reagents*, ed. G. S. Silverman and P. E. Rakita, Marcel Dekker, Inc., New York, 1996, ch. 6, pp. 89–92.
- 16 A. L. Wayda and J. L. Dye, *J. Chem. Educ.*, 1985, **62**, 356.
- 17 W. Trager and J. B. Jensen, *Science*, 1976, **193**, 673.
- 18 COLLECT, Data Collection Software, Nonius B.V., Delft, The Netherlands, 2000.
- 19 Z. Otwinoski and W. Minor, *Methods Enzymol.*, 1997, **276**, 307.
- 20 G. M. Sheldrick, SHELX97, Program for solving crystal structures, University of Göttingen, Göttingen, Germany, 1997.
- 21 L. J. Barbour, X-Seed graphical interface for the SHELX program, University of MissouriColumbia, USA, 1999.